Publications

  1. Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver RN, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez JC, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain J, Ruiz M, Brammer JE, Prakash R, Padmanabhan Iyer S, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos BM, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Jagadeesh D, Brooks TR, Hariharan N, Goodman AM, Hartmann G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS Relapse in T-Cell Lymphoma Index Predicts CNS Relapse in Patients with T- and NK-Cell Lymphomas. Blood Adv. 2024 May 13 [Epub ahead of print]
    View PubMed
  2. Moustafa MA, Ramdial JL, Tsalatsanis A, Khimani F, Dholaria B, Bojanini L, Brooks T, Zain J, Bennani NN, Braunstein Z, Brammer JE, Beitinjaneh A, Jagadeesh D, Weng WK, Kumar A, Kharfan-Dabaja MA, Ahmed S, Murthy HS. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma. Transplant Cell Ther. 2024 May; 30 (5):516.e1-516.e10 Epub 2024 Feb 29
    View PubMed
  3. Ruan GJ, Zanwar S, Ravindran A, Schram S, Abeykoon JP, Hazim A, Young JR, Shah MV, Bennani NN, Jiang L, Morlote D, Rech KL, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. Am J Hematol. 2024 May; 99 (5):871-879 Epub 2024 Feb 26
    View PubMed
  4. Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity. Blood. 2024 Apr 18 [Epub ahead of print]
    View PubMed
  5. Bansal R, Vergidis P, Tosh PK, Wilson J, Hathcock M, Khurana A, Bennani NN, Paludo J, Villasboas JC, Wang Y, Ansell SM, Johnston PB, Freeman C, Lin Y. Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2024 Apr; 30 (4):455.e1-455.e7 Epub 2024 Feb 10
    View PubMed
  6. Burlile JF, Frechette KM, Breen WG, Hwang SR, Higgins AS, Nedved AN, Harmsen WS, Pulsipher SD, Witzig TE, Micallef IN, Hoppe BS, Habermann TM, Thanarajasingam G, Johnston PB, Inwards DJ, Bennani NN, Peterson JL, Stish BJ, Rule WG, Ansell SM, Lester SC. Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy. Blood Adv. 2024 Mar 12; 8 (5):1250-1257
    View PubMed
  7. Chohan KL, Bansal R, Hathcock MA, Paludo J, Bennani NN, Johnston PB, Khurana A, Durani U, Wang Y, Ruff MW, Villasboas Bisneto JC, Ansell SM, Lin Y, Kenderian SS. Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience. Leuk Lymphoma. 2024 Mar; 65 (3):389-393 Epub 2023 Nov 30
    View PubMed
  8. Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27; 8 (4):1042-1050
    View PubMed
  9. Saifi O, Lester SC, Breen WG, Rule WG, Lin Y, Bennani NN, Rosenthal A, Munoz J, Murthy HS, Kharfan-Dabaja MA, Peterson JL, Hoppe BS. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach. Am J Hematol. 2024 Jan; 99 (1):124-134 Epub 2023 Nov 11
    View PubMed
  10. Goyal G, Acosta-Medina AA, Abeykoon JP, Dai C, Ravindran A, Vassallo R, Ryu JH, Shah MV, Bennani NN, Young JR, Bach CR, Ruan GJ, Zanwar S, Tobin WO, Koster MJ, Davidge-Pitts CJ, Gruber LM, Dasari S, Rech KL, Go RS. Long-term outcomes among adults with Langerhans cell histiocytosis. Blood Adv. 2023 Nov 14; 7 (21):6568-6578
    View PubMed
  11. Acosta-Medina AA, Kemps PG, Zondag TCE, Abeykoon JP, Forma-Borst J, Steenwijk EC, Feijen EAM, Teepen JC, Bennani NN, Schram SM, Shah MV, Davidge-Pitts C, Koster MJ, Ryu JH, Vassallo R, Tobin WO, Young JR, Dasari S, Rech K, Ravindran A, Cleven AHG, Verdijk RM, van Noesel CJM, Balgobind BV, Bouma GJ, Saeed P, Bramer JAM, de Groen RAL, Vermaat JSP, van de Sande MAJ, Smit EF, Langerak AW, van Wezel T, Tonino SH, van den Bos C, van Laar JAM, Go RS, Goyal G, van Halteren AGS. BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis. Blood. 2023 Nov 2; 142 (18):1570-1575
    View PubMed
  12. Banks SA, Bhatti MT, Go RS, Abeykoon JP, Acosta-Medina AA, Hazim AZ, Goyal G, Young JR, Koster MJ, Vassallo R, Ryu JH, Davidge-Pitts CJ, Ravindran A, Sartori Valinotti JC, Bennani NN, Shah MV, Rech KL, Garrity JA, Tobin WO. Reply. Ophthalmology 2023 Sep; 130 (9):e33-e34 Epub 2023 June 10
    View PubMed
  13. Breen WG, Young JR, Hathcock MA, Kowalchuk RO, Thorpe MP, Bansal R, Khurana A, Bennani NN, Paludo J, Bisneto JV, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer J. 2023 Aug 18; 13 (1):127
    View PubMed
  14. Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Khurana A, Villasboas JC, Johnston PB, Ansell SM, Iqbal M, Moustafa MA, Murthy HS, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2023 Aug 1; 116 (5):999-1007 Epub 2022 Dec 21
    View PubMed
  15. Macapagal SC, Bennani NN. Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet? Blood Rev. 2023 Jul; 60:101071 Epub 2023 Mar 03
    View PubMed
  16. Chohan KL, Abeykoon JP, Young JR, Tobin WO, Koster MJ, Shah MV, Ryu JH, Vassallo R, Rech KL, Ravindran A, Goyal G, Go RS, Bennani NN. Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma. Haematologica. 2023 Jun 1; 108 (6):1702-1706 Epub 2023 June 01
    View PubMed
  17. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jun; 23 (6):456-462 Epub 2023 Mar 07
    View PubMed
  18. Banks SA, Sartori Valinotti JC, Go RS, Abeykoon JP, Goyal G, Young JR, Koster MJ, Vassallo R, Ryu JH, Davidge-Pitts CJ, Ravindran A, Bennani NN, Shah MV, Rech KL, Tobin WO, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group and Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology. Neurological Manifestations of Histiocytic Disorders. Curr Neurol Neurosci Rep. 2023 Jun; 23 (6):277-286 Epub 2023 May 20
    View PubMed
  19. Bezerra ED, Iqbal M, Munoz J, Khurana A, Wang Y, Maurer MJ, Bansal R, Hathcock MA, Bennani N, Murthy HS, Rosenthal AC, Paludo J, Villasboas JC, Johnston PB, Habermann TM, Ansell SM, Castro JE, Witzig TE, Kharfan-Dabaja MA, Nowakowski GS, Lin Y. Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy. Blood Adv. 2023 Apr 25; 7 (8):1572-1576
    View PubMed
  20. Powell MZ, Mara KC, Bansal R, Hathcock MA, Khurana A, Bennani NN, Wang Y, Paludo J, Bisneto JV, Ansell SM, Johnston PB, Lin Y, Barreto JN. Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients. Cancer Med. 2023 Apr; 12 (8):9228-9235 Epub 2023 Feb 08
    View PubMed
  21. McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D, Bennani N, Thanarajasingam G, Nowakowski G, Porrata L, Thompson C, Micallef I, Johnston P, Ansell S, Paludo J. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023 Feb; 64 (2):371-377 Epub 2022 Nov 23
    View PubMed
  22. Acosta-Medina AA, Johnson IM, Bansal R, Hathcock M, Kenderian SJ, Durani U, Khurana A, Wang Y, Paludo J, Villasboas JC, Bennani NN, Johnston PB, Ansell SM, Lin Y, Alkhateeb HB. Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. Blood Cancer J 2023 Jan 5; 13 (1):7 Epub 2023 Jan 05
    View PubMed
  23. Banks SA, Bhatti MT, Go RS, Abeykoon JP, Acosta-Medina AA, Hazim AZ, Goyal G, Young JR, Koster MJ, Vassallo R, Ryu JH, Davidge-Pitts CJ, Ravindran A, Sartori Valinotti JC, Bennani NN, Shah MV, Rech KL, Garrity JA, Tobin WO, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Ophthalmologic Involvement in Adults with Histiocytic Disorders: Clinical Presentation and Treatment Outcomes. Ophthalmology. 2023 Jan; 130 (1):77-86 Epub 2022 Aug 03
    View PubMed
  24. O'Donoghue DF, Truong HL, Finnes HD, McDonald JS, May HP, Ansell SM, Bennani NN, Habermann TM, Inwards DJ, Johnston PB, Khurana A, Lin Y, Micallef IN, Nowakowski GS, Paludo J, Porrata LF, Thanarajasingam G, Thompson CA, Villasboas JC, Wang Y, Witzig TE, Leung N. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course. JCO Oncol Pract. 2022 Dec; 18 (12):e1908-e1917 Epub 2022 Oct 14
    View PubMed
  25. Abeykoon JP, Rech KL, Young JR, Ravindran A, Ruan GJ, Dasari S, Morlote DM, King RL, Rummage C, Zanwar S, Acosta-Medina AM, Tobin WO, Shah MV, Bennani NN, Vassallo R, Ryu JH, Koster MJ, Davidge-Pitts CJ, Witzig TE, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status. JAMA Oncol. 2022 Dec 1; 8 (12):1816-1820
    View PubMed
  26. Hazim AZ, Acosta-Medina AA, Young JR, Ruan GJ, Abeykoon JP, Ravindran A, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Bennani NN, Rech KL, Shah MV, Witzig TE, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Classical and non-classical phenotypes of Erdheim-Chester disease: Correlating clinical, radiographic and genotypic findings. Br J Haematol 2022 Nov; 199 (3):454-457 Epub 2022 Aug 26
    View PubMed
  27. Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 (10):753-759 Epub 2022 May 23
    View PubMed
  28. Farooqui N, Sy-Go JPT, Miao J, Mehta R, Vaughan LE, Bennani NN, Wang Y, Bansal R, Hathcock MA, Hayman SR, Johnston PB, Villasboas JC, Paludo J, Ansell SM, Leung N, Lin Y, Herrmann SM. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy. Mayo Clin Proc. 2022 Jul; 97 (7):1294-1304
    View PubMed
  29. Bansal R, Novo M, Al Saleh AS, Guerrico AG, Zhang H, Shao Z, Babadi E, Martinez KE, McCoy GA, Hathcock MA, Khurana A, Bennani NN, Paludo J, Wang Y, Ansell SM, Johnston PB, Villasboas JC, Lin Y. Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. Am J Hematol 2022 Jul; 97 (7):E241-E244 Epub 2022 Apr 14
    View PubMed
  30. Zanwar S, Abeykoon JP, Dasari S, Ravindran A, Young JR, Acosta-Medina AA, Rech KL, Schwartz J, Mangold A, Rosenthal A, Bennani NN, Shah MV, Morlote D, Goyal G, Go RS. Clinical and therapeutic implications of BRAF fusions in histiocytic disorders. Blood Cancer J 2022 Jun 28; 12 (6):97 Epub 2022 June 28
    View PubMed
  31. Hu M, Goyal G, Abeykoon JP, Acosta-Medina AA, Ruan GJ, Young JR, Ravindran A, Bennani NN, Shah MV, Vassallo R, Ryu JH, Davidge-Pitts CJ, Koster MJ, Tobin WO, Sartori-Valinotti JC, Rech KL, Go RS. Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis. Blood Cancer J 2022 Jun 3; 12 (6):89 Epub 2022 June 03
    View PubMed
  32. Bennani NN, Kim HJ, Pederson LD, Atherton PJ, Micallef IN, Thanarajasingam G, Nowakowski GS, Witzig T, Feldman AL, Ansell SM. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022 Jun; 10 (6)
    View PubMed
  33. Bennani NN, Tun AM, Carson KR, Geiger JL, Maeda LS, Savage KJ, Rose J, Pinter-Brown L, Lunning MA, Abramson JS, Bartlett NL, Vose JM, Evens AM, Smith SM, Horwitz SM, Ansell SM, Advani RH. Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clin Lymphoma Myeloma Leuk. 2022 May; 22 (5):e300-e309 Epub 2021 Nov 03
    View PubMed
  34. Bennani NN, Tun AM, Carson KR, Geiger JL, Maeda LS, Savage KJ, Rose J, Pinter-Brown L, Lunning MA, Abramson JS, Bartlett NL, Vose JM, Evens AM, Smith SM, Horwitz SM, Ansell SM, Advani RH. Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clin Lymphoma Myeloma Leuk. 2022 Apr; 22 (4):e250-e260 Epub 2021 Oct 16
    View PubMed
  35. Breen WG, Hathcock MA, Young JR, Kowalchuk RO, Bansal R, Khurana A, Bennani NN, Paludo J, Villasboas Bisneto JC, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. J Hematol Oncol 2022 Mar 26; 15 (1):36
    View PubMed
  36. Goyal G, Young JR, Abeykoon JP, Shah MV, Bennani NN, Sartori-Valinotti JC, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Davidge-Pitts CJ, Ravindran A, Rech KL, Go RS. Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experience. Oncologist. 2022 Mar 4; 27 (2):144-148
    View PubMed
  37. Abeykoon JP, Lasho TL, Dasari S, Rech KL, Ranatunga WK, Manske MK, Tischer A, Ravindran A, Young JR, Tobin WO, Flanagan EP, Nowakowski KE, Ruan GJ, Shah MV, Bennani NN, Vassallo R, Ryu JH, Koster MJ, Davidge-Pitts CJ, Patnaik MM, Wu X, Witzig TE, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease. Am J Hematol. 2022 Mar 1; 97 (3):293-302 Epub 2022 Jan 03
    View PubMed
  38. Saifi O, Breen WG, Lester SC, Rule WG, Stish B, Rosenthal A, Munoz J, Herchko SM, Murthy HS, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Wang Y, Khurana A, Bisneto JCV, Johnston PB, Ansell SM, Iqbal M, Tun H, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? Radiother Oncol. 2022 Jan; 166:171-179. Epub 2021 Dec 07.
    View PubMed
  39. Hazim AZ, Ruan GJ, Hu M, Ravindran A, Rech KL, Young JR, Cox CW, Abeykoon JP, Scheckel C, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Bennani NN, Shah MV, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. Am J Hematol. 2021 Dec 01; 96(12):1604-1610. Epub 2021 Oct 08.
    View PubMed
  40. Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J. Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. Hematol Oncol. 2021 Dec; 39(5):658-663. Epub 2021 Aug 28.
    View PubMed
  41. Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Braksick SA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. Am J Hematol 2021 Nov 1; 96 (11):E427-E430 Epub 2021 Sept 07
    View PubMed
  42. Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Braksick SA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. Am J Hematol. 2021 Nov 1; 96(11):E427-E430. Epub 2021 Sep 07.
    View PubMed
  43. King RL, Khurana A, Mwangi R, Fama A, Ristow KM, Maurer MJ, Macon WR, Ansell SM, Bennani NN, Kudva YC, Walker RC, Watt KD, Schwab TR, Kushwaha SS, Cerhan JR, Habermann TM. Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. Hemasphere. 2021 Oct; 5 (10):e640 Epub 2021 Sept 06
    View PubMed
  44. Orellana-Noia VM, Isaac K, Malecek MK, Bartlett NL, Voorhees TJ, Grover NS, Hwang SR, Bennani NN, Hu R, Hill BT, Mou E, Advani RH, Carter J, David KA, Ballard HJ, Svoboda J, Churnetski MC, Magarelli G, Feldman TA, Cohen JB, Evens AM, Portell CA. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. Blood Adv. 2021 Sep 28; 5 (18):3623-3632
    View PubMed
  45. Brumfiel CM, Patel MH, Puri P, Besch-Stokes J, Lester S, Rule WG, Khera N, Sluzevich JC, DiCaudo DJ, Comfere N, Bennani NN, Rosenthal AC, Pittelkow MR, Mangold AR. How to Sequence Therapies in Mycosis Fungoides. Curr Treat Options Oncol. 2021 Sep 27; 22 (11):101 Epub 2021 Sept 27
    View PubMed
  46. Wudhikarn K, Bennani NN. How to Sequence Therapies in Peripheral T Cell Lymphoma. Curr Treat Options Oncol. 2021 Jul 2; 22 (9):74 Epub 2021 July 02
    View PubMed
  47. Melody M, Gandhi S, Rahman ZA, Lengerke-Diaz P, Gannon N, Rosenthal A, Truong T, Novo M, Brandes E, Lange G, Estby B, Johnston P, Ansell S, Bennani NN, Paludo J, Bisneto JV, Ayala E, Tun HW, Murthy HS, Roy V, Foran J, Castro J, Lin Y, Kharfan-Dabaja MA. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. Eur J Haematol. 2021 Jul; 107 (1):48-53 Epub 2021 Apr 15
    View PubMed
  48. Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Blood Cancer J 2021 Jul 1; 11 (7):124 Epub 2021 July 01
    View PubMed
  49. Oishi N, Hundal T, Phillips JL, Dasari S, Hu G, Viswanatha DS, He R, Mai M, Jacobs HK, Ahmed NH, Syrbu SI, Salama Y, Chapman JR, Vega F, Sidhu J, Bennani NN, Epstein AL, Medeiros JL, Clemens MW, Miranda RN, Feldman AL. Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma. Haematologica. 2021 Jun 1; 106 (6):1714-1724 Epub 2021 June 01
    View PubMed
  50. Goyal G, Abeykoon JP, Hu M, Young JR, Shah MV, Bennani NN, Call TG, Hook CC, Pardanani A, Inwards DJ, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Davidge-Pitts CJ, Ravindran A, Rech KL, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. Am J Hematol 2021 May 1; 96 (5):E146-E150 Epub 2021 Feb 19
    View PubMed
  51. Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose JM, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill BT, Miklos DB. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 2021 Apr 1; 137 (13):1832-1835
    View PubMed
  52. Diefenbach CS, Peters BA, Li H, Raphael B, Moskovits T, Hymes K, Schluter J, Chen J, Bennani NN, Witzig TE, Ahn J. Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma. Blood Adv. 2021 Mar 9; 5 (5):1194-1198
    View PubMed
  53. Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J 2021 Mar 2; 11 (3):47 Epub 2021 Mar 02
    View PubMed
  54. Kutzke JL, Leung JG, May HP, Nedved AN, DeFino CE, Bennani NN. Successful Continuation of Clozapine in Conjunction With Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy: Case Report. Clin Lymphoma Myeloma Leuk. 2021 Feb; 21 (2):e194-e197 Epub 2020 Oct 22
    View PubMed
  55. Hwang SR, Higgins A, Castillo Almeida NE, LaPlant B, Maurer MJ, Ansell SM, Witzig TE, Thanarajasingam G, Bennani NN. Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. Leuk Lymphoma 2021 Jan; 62 (1):247-251 Epub 2020 Oct 06
    View PubMed
  56. Hazim AZ, Ruan GJ, Ravindran A, Abeykoon JP, Scheckel C, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Bennani NN, Rech KL, Young JR, Shah MV, Goyal G, Go RS. Efficacy of BRAF-Inhibitor Therapy in BRAF(V600E) -Mutated Adult Langerhans Cell Histiocytosis. Oncologist. 2020 Dec; 25 (12):1001-1004 Epub 2020 Oct 12
    View PubMed
  57. Ruan GJ, Hazim A, Abeykoon JP, Scheckel C, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Bennani NN, Rech KL, Young JR, Shah MV, Goyal G, Go RS. Low-dose vemurafenib monotherapy in BRAF(V600E) -mutated Erdheim-Chester disease. Leuk Lymphoma 2020 Nov; 61 (11):2733-2737 Epub 2020 July 01
    View PubMed
  58. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep 20; 38 (27):3119-3128 Epub 2020 May 13
    View PubMed
  59. Hu G, Phillips JL, Dasari S, Jacobs HK, Luchtel RA, Oishi N, Hundal T, Ahmed NH, Satou A, Epstein AL, Bennani NN, Nowakowski GS, Murray JA, Feldman AL. Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. Leukemia 2020 May; 34 (5):1467-1471 Epub 2019 Dec 13
    View PubMed
  60. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol. 2020 Mar; 95(3):274-281. Epub 2019 Dec 31.
    View PubMed
  61. Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020; 105 (2):348-357 Epub 2020 Jan 31
    View PubMed
  62. Goyal G, Ravindran A, Liu Y, He R, Shah MV, Bennani NN, Patnaik MM, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica 2020; 105 (2):e84-e86 Epub 2020 Jan 31
    View PubMed
  63. Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Davidge-Pitts CJ, Hurtado MD, Ravindran A, Sartori Valinotti JC, Bennani NN, Shah MV, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc. 2019 Oct; 94 (10):2054-2071 Epub 2019 Aug 28
    View PubMed
  64. Satou A, Bennani NN, Feldman AL. Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol. 2019 Oct; 12 (10):833-843 Epub 2019 July 31
    View PubMed
  65. Oishi N, Sartori-Valinotti JC, Bennani NN, Wada DA, He R, Cappel MA, Feldman AL. Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. J Cutan Pathol. 2019 Sep; 46(9):637-644. Epub 2019 May 03.
    View PubMed
  66. Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR. Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. Br J Haematol. 2019 Sep; 186 (6):820-828 Epub 2019 May 28
    View PubMed
  67. Ellin F, Maurer MJ, Srour L, Farooq U, Jerkeman M, Connors JM, Smedby KE, Bennani NN, Ansell SM, Slack GW, Cerhan JR, Relander T, Feldman AL, Savage KJ. Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. Br J Haematol 2019 Aug; 186 (3):e24-e27 Epub 2019 Mar 11
    View PubMed
  68. Luchtel RA, Zimmermann MT, Hu G, Dasari S, Jiang M, Oishi N, Jacobs HK, Zeng Y, Hundal T, Rech KL, Ketterling RP, Lee JH, Eckloff BW, Yan H, Gaonkar KS, Tian S, Ye Z, Kadin ME, Sidhu J, Jiang L, Voss J, Link BK, Syrbu SI, Facchetti F, Bennani NN, Slager SL, Ordog T, Kocher JP, Cerhan JR, Ansell SM, Feldman AL. Recurrent MSC (E116K) mutations in ALK-negative anaplastic large cell lymphoma. Blood. 2019 Jun 27; 133 (26):2776-2789 Epub 2019 May 17
    View PubMed
  69. Goyal G, Lau D, Nagle AM, Vassallo R, Rech KL, Ryu JH, Davidge-Pitts CJ, Tobin WO, Koster MJ, Bennani NN, Shah MV, Liu MC, Go RS, Mayo Clinic Histiocytosis Working Group. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood 2019 Apr 4; 133 (14):1607-1610 Epub 2019 Jan 29
    View PubMed
  70. Goyal G, Lau D, Nagle AM, Vassallo R, Rech KL, Ryu JH, Davidge-Pitts CJ, Tobin WO, Koster MJ, Bennani NN, Shah MV, Liu MC, Go RS, Mayo Clinic Histiocytosis Working Group. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood. 2019 Apr 4; 133(14):1607-1610. Epub 2019 Jan 29.
    View PubMed
  71. Kommalapati A, Tella SH, Go RS, Bennani NN, Goyal G. A population-based analysis of second primary malignancies in T-cell neoplasms. Br J Haematol. 2019 Apr; 185(2):338-342. Epub 2018 Jul 05.
    View PubMed
  72. Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, Macon WR, Micallef INM, King RL, Salomao DR, Witzig TE, Habermann TM, Nowakowski GS. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. Am J Hematol. 2019 Mar; 94 (3):291-298 Epub 2018 Dec 05
    View PubMed
  73. Bennani NN, Ansell SM. Tumor Microenvironment in T-Cell Lymphomas. Cancer Treat Res. 2019; 176:69-82
    View PubMed
  74. Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani NN, Thompson CA, Cerhan JR, Witzig TE. Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker? Nutr Cancer. 2018 Oct; 70 (7):1088-1090 Epub 2018 Sept 20
    View PubMed
  75. Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 2018 Oct; 183 (1):149-152 Epub 2017 Sept 29
    View PubMed
  76. Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, Ketterling RP, Sidhu J, Wang X, Katoh R, Dogan A, Kip NS, Cunningham JM, Sun Z, Baheti S, Porcher JC, Said JW, Jiang L, Hamilton-Dutoit SJ, Moller MB, Norgaard P, Bennani NN, Chng WJ, Huang G, Link BK, Facchetti F, Cerhan JR, d'Amore F, Ansell SM, Feldman AL. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood. 2018 Sep 27; 132 (13):1386-1398 Epub 2018 Aug 09
    View PubMed
  77. Oishi N, Brody GS, Ketterling RP, Viswanatha DS, He R, Dasari S, Mai M, Benson HK, Sattler CA, Boddicker RL, McPhail ED, Bennani NN, Harless CA, Singh K, Clemens MW, Medeiros LJ, Miranda RN, Feldman AL. Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 2018 Aug 2; 132 (5):544-547 Epub 2018 June 19
    View PubMed
  78. Sharma A, Oishi N, Boddicker RL, Hu G, Benson HK, Ketterling RP, Greipp PT, Knutson DL, Kloft-Nelson SM, He R, Eckloff BW, Jen J, Nair AA, Davila JI, Dasari S, Lazaridis KN, Bennani NN, Wu TT, Nowakowski GS, Murray JA, Feldman AL. Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 2018 May 17; 131 (20):2262-2266 Epub 2018 Mar 28
    View PubMed
  79. Sharma A, Oishi N, Boddicker RL, Hu G, Benson HK, Ketterling RP, Greipp PT, Knutson DL, Kloft-Nelson SM, He R, Eckloff BW, Jen J, Nair AA, Davila JI, Dasari S, Lazaridis KN, Bennani NN, Wu TT, Nowakowski GS, Murray JA, Feldman AL. Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood. 2018 May 17; 131(20):2262-2266. Epub 2018 Mar 28.
    View PubMed
  80. Hu G, Dasari S, Asmann YW, Greipp PT, Knudson RA, Benson HK, Li Y, Eckloff BW, Jen J, Link BK, Jiang L, Sidhu JS, Wellik LE, Witzig TE, Bennani NN, Cerhan JR, Boddicker RL, Feldman AL. Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 2018 Feb; 32 (2):565-569 Epub 2017 Oct 13
    View PubMed
  81. Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. J Clin Oncol. 2017 Dec 20; 35 (36):4019-4026 Epub 2017 Oct 26
    View PubMed
  82. Bennani NN, Ansell SM. Peripheral T-cell lymphomas: very little good, mainly the bad and the ugly. Leuk Lymphoma 2017 Oct; 58 (10):2273-2274 Epub 2017 June 02
    View PubMed
  83. Pedersen MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, Bedroske PP, Luoma IM, Sattler CA, Boddicker RL, Bennani NN, Norgaard P, Moller MB, Steiniche T, d'Amore F, Feldman AL. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood 2017 Jul 27; 130 (4):554-557 Epub 2017 May 18
    View PubMed
  84. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: B-cell non-Hodgkin lymphomas. Expert Rev Hematol. 2017 May; 10 (5):405-415 Epub 2017 Apr 24
    View PubMed
  85. Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017 May; 92 (5):448-453 Epub 2017 Mar 10
    View PubMed
  86. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol. 2017 Mar; 10 (3):239-249 Epub 2017 Jan 29
    View PubMed
  87. Bennani-Baiti N, Thanarajasingam G, Ansell S. Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. Expert Rev Clin Immunol. 2016 Jun; 12: (6)673-9.
    View PubMed
  88. Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma. Curr Treat Options Oncol. 2016 May; 17(5):24.
    View PubMed
  89. Bennani-Baiti N, Bennani-Baiti B, Bennani-Baiti N, Baltzer PA. Diagnostic Performance of Breast Magnetic Resonance Imaging in Non-Calcified Equivocal Breast Findings: Results from a Systematic Review and Meta-Analysis. PLoS One. 2016; 11 (8):e0160346 Epub 2016 Aug 02
    View PubMed
  90. Bennani-Baiti N, Ansell S, Feldman AL. Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management. Expert Rev Hematol. 2016; 9 (2):137-50 Epub 2015 Dec 11
    View PubMed
  91. Thanarajasingam G, Bennani NN, Nowakowski GS. Individualized Treatment of Diffuse Large B-cell Lymphoma— The Evolving Role of Molecular-subtype-specific Therapy Oncology & Hematology Review.2015 Nov 2;11:(2):113-4.
  92. Bennani-Baiti B, Yadav S, Flynt L, Bennani-Baiti N, Bennani NN. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol. 2015 Apr 1; 33: (10)1216-7.
    View PubMed
  93. Bennani-Baiti N, Bennani-Baiti IM. Cancer Bioinformatic Methods to Infer Meaningful Data From Small-Size Cohorts. Cancer Inform. 2015; 14:131-9 Epub 2015 Nov 02
    View PubMed
  94. Shrotriya S, Walsh D, Bennani-Baiti N, Bennani NN, Thomas S, Lorton C. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One. 2015; 10: (12)e0143080.
    View PubMed
  95. Sakruti S, Bennani NN, Thota S, Garje R, Fawole A, Elson P, Haddad A, Spiro T, Daw H. Diffuse large B cell lymphoma: role of MYC, BCL2, BCL6 protein expression and translocations Blood.2013 Nov 15;122:(21):5055.
  96. Shrotriya S, Walsh D, Bennani NN. C-Reactive Protein as a Prognostic Indicator in Adult Solid Tumors: A Systematic Review Journal of Pain and Symptom Management .2013 Feb ;45:(2):452-3.
  97. Bennani-Baiti N, Bennani NN, Daw HA, Cotta C, Martin P, Mitchell KW, Ambinder RF, Macklis R, Pollock R, Spiro T. Low-grade follicular lymphoma of the small intestine: a challenge for management. Semin Oncol. 2011 Dec; 38: (6)714-20.
    View PubMed
  98. Bennani NN, Walsh D. Animal models of the cancer anorexia–cachexia syndrome Support Care in Cancer. 2011 Sep ; 19(9):1451-63.
    View PubMed
  99. Bennani NN, Daw H. Primary Hyperfibrinolysis in Liver Disease: A Critical Review Clinical Advances in Hematology and Oncology. 2001 Mar; 9(3):250-2.
    View PubMed
  100. Davis M, Bennani NN, Seyidova-Khoshknabi D, Lagman R, Karafa M, Walsh D. Phase Angle is a Better Predictor of Survival than Muscle Mass in Advanced Cancer Journal of Pain and Symptom Management.2010 Feb 2;39:(2):336-7.
  101. Bennani NN, Walsh D. What is cancer anorexia cachexia syndrome? A historical perspective The Journal of Royal College of Physicians of Edinburgh. 2009 Sep; 39(3):257-62.
    View PubMed
  102. Seyidova-Khoshknabi D, Bennani NN, Kirkova J, Lasheen W, Davis M, Walsh D, Lagman R, LeGrand S. Insomnia in Advanced Cancer Journal of Pain and Symptom Management .2009 Mar 9;37:(3):469.
  103. Bennani NN, Walsh D. C-reactive protein as a prognosis indicator in solid tumors: A systematic review Supportive Care in Cancer.2009 Jan;17:857-1039.
  104. Davis M, Bennani NN, Seyidova-Khoshknabi D, Lagman R, Karafa M, Walsh D. Phase Angle is a Better Predictor of Survival Than Muscle Mass in Advanced Cancer Supportive Care in Cancer.2009 Jan;17:857–1039.
  105. Bennani NN, Davis M. Cytokines and cancer anorexia cachexia syndrome American Journal of Hospice and Palliative Medicine. 2008 Nov ; 25(5):407-11.
    View PubMed
  106. Seyidova-Khoshknabi D, Bennani NN, Kirkova J, Lasheen W, Davis M, Walsh D, Lagman R, LeGrand S. Insomnia in Advanced Cancer Supportive Care in Cancer.2008 Aug 1;16:(6):718.
  107. Bennani NN, Davis M, Walsh D. Cachexias: a 2007 state of the art review of the metabolic and biochemical abnormalities in different clinical models of cachexia Supportive Care in Cancer.2007 Dec 6;15:(6):773-4.
  108. Bennani NN, Walsh D, Davis M. Animal models for cancer cachexia: what are the options? Supportive Care in Cancer. 2007 Dec 6; 15(6):773.
  109. Yin L, Bennani NN, Powell CT. Phorbol Ester-induced apoptosis of C4-2 cells requires both a unique and a redundant protein kinase C signaling pathway Journal of Biological Chemistry. 2005 Feb 18; 280(7):5533-41.
    View PubMed